Duivenvoorden WCM - Search Results

1

Cardiovascular risk in ADT recipients: does the type of ADT matter?

Pinthus JH, Duivenvoorden WCM. Pinthus JH, et al. Among authors: duivenvoorden wcm. Prostate Cancer Prostatic Dis. 2024 Apr 25. doi: 10.1038/s41391-024-00832-0. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38664503 Review. No abstract available.

2

Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE^-/-:Ins2^+/Akita mouse model.

Duivenvoorden WCM, Naeim M, Hopmans SN, Yousef S, Werstuck GH, Dason S, Pinthus JH. Duivenvoorden WCM, et al. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):389-397. doi: 10.1038/s41391-020-00288-y. Epub 2020 Sep 28. Prostate Cancer Prostatic Dis. 2021. PMID: 32989260

3

Correction: Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE^-/-:Ins2^+/Akita mouse model.

Duivenvoorden WCM, Naeim M, Hopmans SN, Yousef S, Werstuck GH, Dason S, Pinthus JH. Duivenvoorden WCM, et al. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):596. doi: 10.1038/s41391-021-00408-2. Prostate Cancer Prostatic Dis. 2022. PMID: 34413483 No abstract available.

4

Adiponectin inhibits oxidative stress in human prostate carcinoma cells.

Lu JP, Hou ZF, Duivenvoorden WC, Whelan K, Honig A, Pinthus JH. Lu JP, et al. Prostate Cancer Prostatic Dis. 2012 Mar;15(1):28-35. doi: 10.1038/pcan.2011.53. Epub 2012 Jan 17. Prostate Cancer Prostatic Dis. 2012. PMID: 22249290

5

Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo.

Duivenvoorden WC, Beatty LK, Lhotak S, Hill B, Mak I, Paulin G, Gallino D, Popovic S, Austin RC, Pinthus JH. Duivenvoorden WC, et al. Br J Cancer. 2013 Feb 5;108(2):327-33. doi: 10.1038/bjc.2012.574. Epub 2013 Jan 15. Br J Cancer. 2013. PMID: 23322200 Free PMC article.

6

Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeutics.

Paschos A, Pandya R, Duivenvoorden WC, Pinthus JH. Paschos A, et al. Prostate Cancer Prostatic Dis. 2013 Sep;16(3):217-25. doi: 10.1038/pcan.2013.13. Epub 2013 May 14. Prostate Cancer Prostatic Dis. 2013. PMID: 23670256 Review.

7

Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms.

Tivesten Å, Pinthus JH, Clarke N, Duivenvoorden W, Nilsson J. Tivesten Å, et al. Urol Oncol. 2015 Nov;33(11):464-75. doi: 10.1016/j.urolonc.2015.05.030. Epub 2015 Jun 30. Urol Oncol. 2015. PMID: 26141678 Review.

8

Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?

Zareba P, Duivenvoorden W, Leong DP, Pinthus JH. Zareba P, et al. Ther Adv Urol. 2016 Apr;8(2):118-29. doi: 10.1177/1756287215617872. Epub 2015 Nov 30. Ther Adv Urol. 2016. PMID: 27034724 Free PMC article. Review.

9

Elevated C-Peptides, Abdominal Obesity, and Abnormal Adipokine Profile are Associated With Higher Gleason Scores in Prostate Cancer.

Di Sebastiano KM, Pinthus JH, Duivenvoorden WC, Patterson L, Dubin JA, Mourtzakis M. Di Sebastiano KM, et al. Prostate. 2017 Feb;77(2):211-221. doi: 10.1002/pros.23262. Epub 2016 Oct 4. Prostate. 2017. PMID: 27699825

10

Does androgen-deprivation therapy for prostate cancer increase the risk for thromboembolic disease?

Pinthus JH, Duivenvoorden WC. Pinthus JH, et al. Can Urol Assoc J. 2017 Jan-Feb;11(1-2):39-40. doi: 10.5489/cuaj.4394. Can Urol Assoc J. 2017. PMID: 28443143 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page